Business Context and Reporting Period
Tenon Medical, Inc. (TNON) is a medical device company developing The Catamaran™ SI Joint Fusion System, a less invasive implant for treating sacroiliac joint dysfunction. The company is a smaller reporting company and an emerging growth company. This summary covers the quarterly period ended September 30, 2024 (Q3 2024), and the nine months ended September 30, 2024 (YTD 2024).
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Revenue | $0.89 million | $0.94 million | $2.51 million | $2.12 million |
| Gross Profit | $0.42 million | $0.54 million | $1.36 million | $0.68 million |
| Gross Margin | 47% | 57% | 54% | 32% |
| Net Loss | $(3.18) million | $(3.33) million | $(10.59) million | $(12.45) million |
| Cash and Equivalents (End of Period) | $9.16 million | $3.37 million | $9.16 million | $3.37 million |
| Debt | $0 | $1.17 million | $0 | $1.17 million |
Note: All figures in millions unless otherwise noted. Debt was fully converted to equity in Q1 2024.
Material Changes vs. Prior Period
- Revenue: Q3 2024 revenue decreased 6% compared to Q3 2023, driven by a 15% decrease in surgical procedures due to sales restructuring and reimbursement pre-authorization delays. However, YTD 2024 revenue increased 18% compared to YTD 2023.
- Profitability: Net loss narrowed slightly in Q3 2024 ($3.18M vs $3.33M) and YTD 2024 ($10.59M vs $12.45M) due to reduced operating expenses.
- Operating Expenses: Total operating expenses decreased 7% in Q3 and 10% YTD. Sales and marketing expenses dropped significantly (21% in Q3, 26% YTD) primarily due to the absence of one-time transition fees paid in 2023.
- Liquidity: Cash balances increased from $2.43 million at year-end 2023 to $9.16 million at September 30, 2024, driven by financing activities.
- Debt Elimination: Convertible notes payable outstanding at December 31, 2023, were fully prepaid and converted into Series A Preferred Stock in February 2024.
Guidance, Outlook, and Risks
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern for the next 12 months. Current cash reserves are insufficient to fund operations without additional capital.
- Capital Raising: The company plans to raise additional capital through public or private equity offerings, debt financings, or collaborations. Recent activities included a public offering in September 2024 and private placements of Series A and Series B Preferred Stock.
- Stock Splits: The company effected a 1-for-8 reverse stock split in September 2024 to regain compliance with Nasdaq listing requirements regarding minimum bid price.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of September 30, 2024, citing a material weakness due to a lack of segregation of duties.
- Outlook: The company expects to incur additional operating losses in the foreseeable future as it continues product development and commercialization.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise given the "substantial doubt" going concern warning.
- Revenue Drivers: Confirm the status of reimbursement pre-authorizations and the impact of the sales restructuring on future procedure volumes.
- Dilution: Review the terms of the newly issued Series A and Series B Preferred Stock and the warrant inducement agreement for potential dilution effects.
- Internal Controls: Monitor progress on remediating the material weakness in internal controls over financial reporting.
- Accrued Commissions: Note the significant liability ($2.14 million) related to the terminated sales representative agreement and its impact on future cash outflows.